March 19, 2018 / 11:07 AM / in 3 months

BRIEF-MediWound Reports Q4 Loss Per Share $0.09

* MEDIWOUND REPORTS FOURTH QUARTER AND FISCAL YEAR 2017 FINANCIAL RESULTS

* Q4 LOSS PER SHARE $0.09

* Q4 EARNINGS PER SHARE VIEW $-0.17 — THOMSON REUTERS I/B/E/S

* ANNOUNCES DISCUSSIONS REGARDING POTENTIAL STRATEGIC TRANSACTION

* HAVE BEEN APPROACHED BY ANOTHER CO TO CONSIDER STRATEGIC TRANSACTION AND ENGAGED, IN THAT RESPECT, IN DISCUSSIONS

* ‍REVENUES FOR Q4 OF 2017 WERE $0.5 MILLION, A 23% INCREASE COMPARED TO Q4 OF 2016​

* BOARD HAS RETAINED MOELIS & COMPANY LLC TO ASSIST US IN EVALUATION OF POTENTIAL OPPORTUNITY

* EXPECT CASH USE FOR OPERATING ACTIVITIES IN 2018 TO BE IN RANGE OF $14.0 MILLION TO $16.0 MILLION

* PLAN TO COMPLETE RECRUITMENT OF 175 PATIENTS TO ONGOING NEXOBRID U.S. PHASE 3 DETECT STUDY AROUND MID-2018

* PLAN TO REPORT PRIMARY, SECONDARY AND SAFETY ACUTE TOPLINE DATA FROM NEXOBRID U.S. PHASE 3 DETECT STUDY AROUND YEAR-END Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below